Levodopa Equivalent Dose Conversion Factors: An Updated Proposal Including Opicapone and Safinamide.
作者信息
Schade Sebastian, Mollenhauer Brit, Trenkwalder Claudia
机构信息
Department of Clinical Neurophysiology University Medical Center Göttingen Göttingen Germany.
Paracelsus-Elena-Klinik Klinikstr. 16, 34128 Kassel Germany.
出版信息
Mov Disord Clin Pract. 2020 Mar 16;7(3):343-345. doi: 10.1002/mdc3.12921. eCollection 2020 Apr.
Abstract
摘要
相似文献
1
Levodopa Equivalent Dose Conversion Factors: An Updated Proposal Including Opicapone and Safinamide.左旋多巴等效剂量转换因子：一项包括奥匹卡朋和沙芬酰胺的更新提案。
Mov Disord Clin Pract. 2020 Mar 16;7(3):343-345. doi: 10.1002/mdc3.12921. eCollection 2020 Apr.
2
Rasagiline and safinamide as a dopamine-sparing therapy for Parkinson's disease.雷沙吉兰和沙芬酰胺作为一种多巴胺保留疗法治疗帕金森病。
Acta Neurol Scand. 2019 Jul;140(1):23-31. doi: 10.1111/ane.13096. Epub 2019 Apr 22.
3
Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.奥匹卡朋作为帕金森病患者左旋多巴辅助治疗药物，用于治疗剂末运动波动：一项随机、双盲、对照试验。
Lancet Neurol. 2016 Feb;15(2):154-165. doi: 10.1016/S1474-4422(15)00336-1. Epub 2015 Dec 23.
4
Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson's Disease: A Post-Hoc Analysis.沙芬酰胺对中晚期帕金森病异动症的长期影响：一项事后分析
J Parkinsons Dis. 2015;5(3):475-81. doi: 10.3233/JPD-150569.
5
Brain and peripheral pharmacokinetics of levodopa in the cynomolgus monkey following administration of opicapone, a third generation nitrocatechol COMT inhibitor.阿扑卡朋（第三代硝替卡朋）给药后食蟹猴脑及外周组织的左旋多巴药代动力学
Neuropharmacology. 2014 Feb;77:334-41. doi: 10.1016/j.neuropharm.2013.10.014. Epub 2013 Oct 19.
6
Pharmacological profile of opicapone, a third-generation nitrocatechol catechol-O-methyl transferase inhibitor, in the rat.第三代硝基邻苯二酚儿茶酚-O-甲基转移酶抑制剂奥匹卡朋在大鼠体内的药理学特性
Br J Pharmacol. 2015 Apr;172(7):1739-52. doi: 10.1111/bph.13020. Epub 2015 Jan 20.
7
Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson's Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLE.沙芬酰胺作为左旋多巴的附加疗法用于中晚期帕金森病波动型患者：016研究和SETTLE研究的事后分析
J Parkinsons Dis. 2016;6(1):165-73. doi: 10.3233/JPD-150700.
8
Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease.恩他卡朋增效治疗与转换治疗对帕金森病运动波动患者的疗效。
Neurology. 2018 May 22;90(21):e1849-e1857. doi: 10.1212/WNL.0000000000005557. Epub 2018 Apr 25.
9
Real life evaluation of safinamide effectiveness in Parkinson's disease.真实世界中评估沙芬酰胺在帕金森病中的疗效。
Neurol Sci. 2018 Apr;39(4):733-739. doi: 10.1007/s10072-018-3272-y. Epub 2018 Feb 13.
10
Noninvasive options for 'wearing-off' in Parkinson's disease: a clinical consensus from a panel of UK Parkinson's disease specialists.帕金森病“剂末现象”的非侵入性治疗选择：来自英国帕金森病专家小组的临床共识
Neurodegener Dis Manag. 2018 Oct;8(5):349-360. doi: 10.2217/nmt-2018-0020. Epub 2018 Jul 5.
引用本文的文献
1
Exploring the relationship between orthostatic hypotension and gait in people with Parkinson's disease.探索帕金森病患者体位性低血压与步态之间的关系。
Clin Auton Res. 2025 Sep 6. doi: 10.1007/s10286-025-01149-1.
2
Quantitative analysis of gait parameters in Parkinson's disease and the clinical significance.帕金森病步态参数的定量分析及其临床意义。
Front Neurol. 2025 Aug 20;16:1527020. doi: 10.3389/fneur.2025.1527020. eCollection 2025.
3
Comparative study of autonomic dysfunction between Parkinson's disease with LRRK2, PRKN, and GBA mutations.携带LRRK2、PRKN和GBA基因突变的帕金森病患者自主神经功能障碍的比较研究
Front Neurol. 2025 Aug 19;16:1657824. doi: 10.3389/fneur.2025.1657824. eCollection 2025.
4
Parkinson's disease medication adjustments based on wearable device information compared to other methods: randomized clinical trial.与其他方法相比，基于可穿戴设备信息进行帕金森病药物调整：随机临床试验
NPJ Parkinsons Dis. 2025 Aug 20;11(1):249. doi: 10.1038/s41531-025-00977-2.
5
Early parkinson's disease: levodopa requirements are associated with the striatal DaT-uptake.早期帕金森病：左旋多巴需求量与纹状体多巴胺转运体摄取有关。
J Neural Transm (Vienna). 2025 Aug 16. doi: 10.1007/s00702-025-02999-9.
6
CSF phospho-tau levels at Parkinson's disease onset predict the risk for development of motor complications.帕金森病发病时脑脊液磷酸化tau蛋白水平可预测运动并发症的发生风险。
J Neurol. 2025 Aug 13;272(9):573. doi: 10.1007/s00415-025-13325-4.
7
Effect of Safinamide on Non-Motor Symptoms and Quality of Life in Parkinson's Disease Patients According to Sex, Age, Disease Duration and Levodopa Equivalent Daily Dose.根据性别、年龄、病程和左旋多巴等效日剂量评估沙芬酰胺对帕金森病患者非运动症状和生活质量的影响
Brain Sci. 2025 Jun 20;15(7):666. doi: 10.3390/brainsci15070666.
8
Detecting delirium in Parkinson's disease: an evaluation of diagnostic accuracy of bedside tools.帕金森病中谵妄的检测：床边工具诊断准确性的评估
Age Ageing. 2025 Jul 1;54(7). doi: 10.1093/ageing/afaf197.
9
Transformer-based long-term predictor of subthalamic beta activity in Parkinson's disease.基于Transformer的帕金森病丘脑底核β活动长期预测器。
NPJ Parkinsons Dis. 2025 Jul 12;11(1):210. doi: 10.1038/s41531-025-01011-1.
10
Rotigotine Patch is Effective for Levodopa (L-Dopa)-Induced Dyspnea: A Case Report.罗替戈汀贴片对左旋多巴（L-多巴）诱发的呼吸困难有效：一例报告
Cureus. 2025 Jun 2;17(6):e85258. doi: 10.7759/cureus.85258. eCollection 2025 Jun.
本文引用的文献
1
Long-term efficacy of opicapone in fluctuating Parkinson's disease patients: a pooled analysis of data from two phase 3 clinical trials and their open-label extensions.伴有波动症状的帕金森病患者中单胺氧化酶-B 抑制剂奥匹卡朋的长期疗效：两项 III 期临床试验及其开放性扩展研究的汇总分析
Eur J Neurol. 2019 Jul;26(7):953-960. doi: 10.1111/ene.13914. Epub 2019 Mar 25.
2
Safinamide: an add-on treatment for managing Parkinson's disease.沙芬酰胺：一种用于治疗帕金森病的附加疗法。
Clin Pharmacol. 2018 Apr 5;10:31-41. doi: 10.2147/CPAA.S137740. eCollection 2018.
3
Are There Benefits in Adding Catechol-O Methyltransferase Inhibitors in the Pharmacotherapy of Parkinson's Disease Patients? A Systematic Review.在帕金森病患者的药物治疗中加入儿茶酚-O-甲基转移酶抑制剂是否有益？系统评价。
J Parkinsons Dis. 2018;8(2):217-231. doi: 10.3233/JPD-171225.
4
Optimizing extended-release carbidopa/levodopa in Parkinson disease: Consensus on conversion from standard therapy.优化帕金森病缓释型卡比多巴/左旋多巴治疗：从标准疗法转换的共识
Neurol Clin Pract. 2017 Feb;7(1):86-93. doi: 10.1212/CPJ.0000000000000316.
5
Systematic review of levodopa dose equivalency reporting in Parkinson's disease.帕金森病左旋多巴剂量等效报告的系统评价。
Mov Disord. 2010 Nov 15;25(15):2649-53. doi: 10.1002/mds.23429.
Zotero 插件